Grant: Discovery Grants Program - Individual
University of Western Ontario
$30,000.00
Cellular and molecular mechanisms in Prostaglandin E2 mediated lymphangiogenesis
EF 2016-17
Résumé
Background: We discovered that COX-2 expression in breast cancer promotes lymphangiogenesis due to PGE2-stimulated VEGF-C/D production by cancer cells and macrophages (mf), following activation of the PGE receptor EP4 on these cells and lymphatic endothelial cells (LEC).
Hypothesis: PGE2 is a physiological promoter of lymphangiogenesis caused by activation of EP4 on LECs and mf to upregulate VEGF-C/D production in situ.
Objectives: (1) Dissect cellular/molecular processes in PGE2-mediated lymphangiogenesis using LECs in vitro; (2) Identify the role of EP4 on mf in stimulating lymphangiogenesis in vitro; (3) Identify cellular/molecular partners in PGE2-mediated lymphangiogenesis in vivo.
Experimental plans:
Aim 1.Lymphatic sprouting in vivo involves proliferation, migration and tube formation by the micro-vascular LEC that can be measured in vitro. We shall use LEC to measure VEGF-R-3 expression (mRNA with qPCR, protein with western blot); VEGF-C/D production (qPCR for mRNA, ELISA for protein); Proliferation (BrdU uptake , 8-16 h); Migration (24 h) through micro-porous (8 µm pores) membranes; Capillary-like tube formation (12 -24 h) on growth factor-reduced matrigel. Each function will employ 12 hr serum-starved LEC +/- PGE2 or EP4 agonists or VEGF-C (+ve control). EP4 dependence of all functions will be tested with an EP4 antagonist or EP4 knockdown in the LEC. Dependence of the functions on EP4 signaling (PI3k/AKT, MAPK phosphorylation) will be tested with EP4 agonists and specific pathway inhibitors.
Aim 2. Measure (a) tubulogenesis by the LEC in the presence of a mf cell line or its cell-free supernatants, and (b) the effects of pre-treating mf with EP4 antagonists or EP4 knockdown of mf on VEGF-C/D production by mf and tube formation by the LEC.
Aim 3. Employ Directed In Vivo Lymphangiogenesis Assay: implant angio-reactors containing matrigel with or without PGE2, or an EP4 agonist or VEGF-C (+ve control) under the dorsal skin in nude mice and 9d later measure lymphangiogenesis by 3 approaches: (a) immunoflourescence of labeled LYVE-1 protein, (b) qPCR for LYVE-1 mRNA and (c) direct counting of lymphatic vessels in cryo-sections dual immuno-labeled for VEGF-C/D and LEC markers LYVE-1 or PROX-1 or podoplanin. We shall also quantify VEGF-C/D-producing mf in situ by double-labeling for F4/80(mf marker) & VEGF-C/D. Treating mice with an EP4 antagonist will test EP4 dependence of the cells contributing to lymphangiogenesis in vivo.
Significance: Understanding basic mechanisms in lymphatic development by a physiological regulator PGE2
Programme
Discovery Grants Program - Individual
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
RGPIN-2015-03905
Name nom
Lala, Peeyush
Department département
Anatomy and Cell Biology - Anatomy and Cell Biology
Organization id
36
Institution établissement
University of Western Ontario
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2016
Competition year année de concours
2015
Award amount
30000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
1501
Committee name en
Genes, Cells and Molecules
Committee name fr
Gènes, cellules et molécules
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
5111
Research subject group en
Cell biology
Research subject group fr
Biologie cellulaire
Research subject en
Signal transduction
Research subject fr
Transduction de signal
Partie
2
Nb partie
5
Application title
Cellular and molecular mechanisms in Prostaglandin E2 mediated lymphangiogenesis
Keyword
NSERC
Application summary
Background: We discovered that COX-2 expression in breast cancer promotes lymphangiogenesis due to PGE2-stimulated VEGF-C/D production by cancer cells and macrophages (mf), following activation of the PGE receptor EP4 on these cells and lymphatic endothelial cells (LEC).
Hypothesis: PGE2 is a physiological promoter of lymphangiogenesis caused by activation of EP4 on LECs and mf to upregulate VEGF-C/D production in situ.
Objectives: (1) Dissect cellular/molecular processes in PGE2-mediated lymphangiogenesis using LECs in vitro; (2) Identify the role of EP4 on mf in stimulating lymphangiogenesis in vitro; (3) Identify cellular/molecular partners in PGE2-mediated lymphangiogenesis in vivo.
Experimental plans:
Aim 1.Lymphatic sprouting in vivo involves proliferation, migration and tube formation by the micro-vascular LEC that can be measured in vitro. We shall use LEC to measure VEGF-R-3 expression (mRNA with qPCR, protein with western blot); VEGF-C/D production (qPCR for mRNA, ELISA for protein); Proliferation (BrdU uptake , 8-16 h); Migration (24 h) through micro-porous (8 µm pores) membranes; Capillary-like tube formation (12 -24 h) on growth factor-reduced matrigel. Each function will employ 12 hr serum-starved LEC +/- PGE2 or EP4 agonists or VEGF-C (+ve control). EP4 dependence of all functions will be tested with an EP4 antagonist or EP4 knockdown in the LEC. Dependence of the functions on EP4 signaling (PI3k/AKT, MAPK phosphorylation) will be tested with EP4 agonists and specific pathway inhibitors.
Aim 2. Measure (a) tubulogenesis by the LEC in the presence of a mf cell line or its cell-free supernatants, and (b) the effects of pre-treating mf with EP4 antagonists or EP4 knockdown of mf on VEGF-C/D production by mf and tube formation by the LEC.
Aim 3. Employ Directed In Vivo Lymphangiogenesis Assay: implant angio-reactors containing matrigel with or without PGE2, or an EP4 agonist or VEGF-C (+ve control) under the dorsal skin in nude mice and 9d later measure lymphangiogenesis by 3 approaches: (a) immunoflourescence of labeled LYVE-1 protein, (b) qPCR for LYVE-1 mRNA and (c) direct counting of lymphatic vessels in cryo-sections dual immuno-labeled for VEGF-C/D and LEC markers LYVE-1 or PROX-1 or podoplanin. We shall also quantify VEGF-C/D-producing mf in situ by double-labeling for F4/80(mf marker) & VEGF-C/D. Treating mice with an EP4 antagonist will test EP4 dependence of the cells contributing to lymphangiogenesis in vivo.
Significance: Understanding basic mechanisms in lymphatic development by a physiological regulator PGE2